High p16 expression and heterozygous rb1 loss are biomarkers for cdk4/6 inhibitor resistance in er+ breast cancer

HIGHLIGHTS

• who: Marta Palafox from the (UNIVERSITY) have published the research work: High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer, in the Journal: (JOURNAL) of 22/02/2021
• what: The authors show that p16 overexpression is associated with reduced antitumor activity of CDK4/6 inhibitors in patient-derived xenografts (n=37) and estrogen receptor-positive breast cancer cell lines, as well as reduced response of early and advanced breast cancer patients to CDK4/6 inhibitors (n=89). The authors aimed at evaluating whether p16 and cyclin . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.